Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

Journal of Experimental Medicine

Volumn 208, Issue 11, 2011, Pages 2155-2158

  Pellicano, Francesca ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ARACHIDONATE 5 LIPOXYGENASE; ARSENIC TRIOXIDE; BREAKPOINT CLUSTER REGION PROTEIN; FINGOLIMOD; IMATINIB; JANUS KINASE 2; LY 364947; MAMMALIAN TARGET OF RAPAMYCIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 6; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZILEUTON;

ACUTE LEUKEMIA; ARTICLE; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; STEM CELL; UPREGULATION;

ANIMALS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-6; SIGNAL TRANSDUCTION;

EID: 80055113098     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20112087     Document Type: Article

References (29)

1. Austin, T.W., G.P. Solar, F.C. Ziegler, L. Liem, and W. Matthews. 1997. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood. 89:3624-3635.
2. Bernardi, R., I. Guernah, D. Jin, S. Grisendi, A. Alimonti, J. Teruya-Feldstein, C. Cordon-Cardo, M.C. Simon, S. Rafii, and P.P. Pandolfi. 2006. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature. 442:779-785. http://dx.doi.org/10.1038/nature05029
3. Bhatia, R., M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber, M.L. Slovak, and S.J. Forman. 2003. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 101:4701-4707. http://dx.doi .org/10.1182/blood-2002-09-2780
4. Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857-868. http://dx.doi.org/10.1016/S0092-8674(00)80595-4
5. Carayol, N., E. Vakana, A. Sassano, S. Kaur, D.J. Goussetis, H. Glaser, B.J. Druker, N.J. Donato, J.K. Altman, S. Barr, and L.C. Platanias. 2010. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. USA. 107:12469-12474. http://dx.doi.org/10.1073/pnas.1005114107
6. Chen, Y., Y. Hu, H. Zhang, C. Peng, and S. Li. 2009. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 41:783-792. http://dx.doi.org/10.1038/ng.389
7. Chen, Y., C. Sullivan, C. Peng, Y. Shan, Y. Hu, D. Li, and S. Li. 2011. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 118:390-400. http://dx.doi.org/10.1182/blood-2010-11-316760
8. Druker, B.J., S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566. http://dx.doi.org/10.1038/nm0596-561
9. Duy, C., C. Hurtz, S. Shojaee, L. Cerchietti, H. Geng, S. Swaminathan, L. Klemm, S.M. Kweon, R. Nahar, M. Braig, et al. 2011. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 473:384-388. http://dx.doi.org/10.1038/nature09883
10. Fernández de Mattos, S., A. Essafi, I. Soeiro, A.M. Pietersen, K.U. Birkenkamp, C.S. Edwards, A. Martino, B.H. Nelson, J.M. Francis, M.C. Jones, et al. 2004. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol. Cell. Biol. 24:10058-10071. http://dx.doi.org/10.1128/MCB.24.22.10058-10071.2004
11. Graham, S.M., H.G. Jørgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond, and T.L. Holyoake. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 99:319-325. http://dx.doi.org/10.1182/blood.V99.1.319
12. Hurtz, C., K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y.-M. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M.C. Müller, et al. 2011. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208:2163-2174.
13. Ilaria, R.L. Jr., and R.A. Van Etten. 1996. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704-31710. http://dx.doi.org/10.1074/jbc.271.49.31704
14. Ito, K., R. Bernardi, A. Morotti, S. Matsuoka, G. Saglio, Y. Ikeda, J. Rosenblatt, D.E. Avigan, J. Teruya-Feldstein, and P.P. Pandolfi. 2008. PML targeting eradicates quiescent leukaemiainitiating cells. Nature. 453:1072-1078. http://dx.doi.org/10.1038/nature07016
15. Komatsu, N., T. Watanabe, M. Uchida, M. Mori, K. Kirito, S. Kikuchi, Q. Liu, T. Tauchi, K. Miyazawa, H. Endo, et al. 2003. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J. Biol. Chem. 278:6411-6419. http://dx.doi.org/10.1074/jbc.M211562200
16. Lee, J.Y., D. Nakada, O.H. Yilmaz, Z. Tothova, N.M. Joseph, M.S. Lim, D.G. Gilliland, and S.J. Morrison. 2010. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell. 7:593-605. http://dx.doi.org/10.1016/j.stem.2010.09.015
17. Mahon, F.X., D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. 2010. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11:1029-1035. http://dx.doi.org/10.1016/S1470-2045(10)70233-3
18. Naka, K., T. Hoshii, T. Muraguchi, Y. Tadokoro, T. Ooshio, Y. Kondo, S. Nakao, N. Motoyama, and A. Hirao. 2010. TGFbeta-FOXO signalling maintains leukaemiainitiating cells in chronic myeloid leukaemia. Nature. 463:676-680. http://dx.doi.org/10.1038/nature08734
19. Neubauer, H., A. Cumano, M. Müller, H. Wu, U. Huffstadt, and K. Pfeffer. 1998. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 93:397-409. http://dx.doi.org/10.1016/S0092-8674(00)81168-X
20. Neviani, P., R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, S. Liu, H. Mao, J.S. Chang, A. Galietta, A. Uttam, et al. 2005. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8:355-368. http://dx.doi.org/10.1016/j.ccr.2005.10.015
21. Neviani, P., R. Santhanam, J.J. Oaks, A.M. Eiring, M. Notari, B.W. Blaser, S. Liu, R. Trotta, N. Muthusamy, C. Gambacorti-Passerini, et al. 2007. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117:2408-2421. http://dx.doi.org/10.1172/JCI31095
22. Peng, C., Y. Chen, Z. Yang, H. Zhang, L. Osterby, A.G. Rosmarin, and S. Li. 2010. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood. 115:626-635. http://dx.doi.org/10.1182/blood-2009-06-228130
23. Rowley, J.D. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:290-293. http://dx.doi.org/10.1038/243290a0
24. Samanta, A.K., S.N. Chakraborty, Y. Wang, H. Kantarjian, X. Sun, J. Hood, D. Perrotti, and R.B. Arlinghaus. 2009. Jak2 inhibition deactivates Lyn kinase through the SETPP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 28:1669-1681. http://dx.doi.org/10.1038/onc.2009.7
25. Stambolic, V., A. Suzuki, J.L. de la Pompa, G.M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J.M. Penninger, D.P. Siderovski, and T.W. Mak. 1998. Negative regulation of PKB/Aktdependent cell survival by the tumor suppressor PTEN. Cell. 95:29-39. http://dx.doi.org/10.1016/S0092-8674(00)81780-8
26. Tothova, Z., R. Kollipara, B.J. Huntly, B.H. Lee, D.H. Castrillon, D.E. Cullen, E.P. McDowell, S. Lazo-Kallanian, I.R. Williams, C. Sears, et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128:325-339. http://dx.doi.org/10.1016/j.cell.2007.01.003
27. Xie, S., H. Lin, T. Sun, and R.B. Arlinghaus. 2002. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 21:7137-7146. http://dx.doi.org/10.1038/sj.onc.1205942
28. Yilmaz, O.H., R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, H. Wu, and S.J. Morrison. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475-482. http://dx.doi.org/10.1038/nature04703
29. Zhou, L.L., Y. Zhao, A. Ringrose, D. DeGeer, E. Kennah, A.E. Lin, G. Sheng, X.J. Li, A. Turhan, and X. Jiang. 2008. AHI-1 interacts with BCRABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/ progenitor cells. J. Exp. Med. 205:2657-2671. http://dx.doi.org/10.1084/jem.20072316